CX3CL1 (fractalkine) and CX3CR1 expression in myelin oligodendrocyte glycoprotein-induced experimental autoimmune encephalomyelitis: kinetics and cellular origin

Dan Sunnemark*†1, Sana Eltayeb†2, Maria Nilsson1, Erik Wallström2, Hans Lassmann3, Tomas Olsson2, Anna-Lena Berg4 and Anders Ericsson-Dahlstrand1

Address: 1Department of Molecular Sciences, AstraZeneca R&D Södertälje, S-151 85 Södertälje, Sweden, 2Neuroimmunology Unit, Department of Clinical Neuroscience, Karolinska Institutet, S-171 76 Stockholm, Sweden, 3Neurological Institute, University of Vienna, Austria and 4Safety Assessment, AstraZeneca R&D Södertälje, S-151 85, Södertälje, Sweden

Published: 29 July 2005

Received: 03 May 2005

Accepted: 29 July 2005

Published by BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Background: Multiple sclerosis (MS) is a chronic inflammatory disease of the central nervous system (CNS). It is associated with local activation of microglia and astroglia, infiltration of activated macrophages and T cells, active degradation of myelin and damage to axons and neurons. The proposed role for CX3CL1 (fractalkine) in the control of microglia activation and leukocyte infiltration places this chemokine and its receptor CX3CR1 in a potentially strategic position to control key aspects in the pathological events that are associated with development of brain lesions in MS. In this study, we examine this hypothesis by analyzing the distribution, kinetics, and cellular origin of CX3CL1 and CX3CR1 mRNA expression in the CNS of rats with an experimentally induced MS-like disease, myelin oligodendrocyte glycoprotein (MOG)-induced autoimmune encephalomyelitis (EAE).

Methods: The expression of CX3CL1 and its receptor CX3CR1 was studied with in situ hybridization histochemical detection of their mRNA with radio labeled cRNA probes in combination with immunohistochemical staining of phenotypic cell markers. Both healthy rat brains and brains from rats with MOG EAE were analyzed. In defined lesional stages of MOG EAE, the number of CX3CR1 mRNA-expressing cells and the intensity of the in situ hybridization signal were determined by image analysis. Data were statistically evaluated by ANOVA, followed by Tukey’s multiple comparison test.

Results: Expression of CX3CL1 mRNA was present within neuronal-like cells located throughout the neuraxis of the healthy rat. Expression of CX3CL1 remained unaltered in the CNS of rats with MOG-induced EAE, with the exception of an induced expression in astrocytes within inflammatory...
lesions. Notably, the brain vasculature of healthy and encephalic animals did not exhibit signs of CX3CL1 mRNA expression. The receptor, CX3CR1, was expressed by microglial cells in all regions of the healthy brain. Induction of MOG-induced EAE was associated with a distinct accumulation of CX3CR1 mRNA expressing cells within the inflammatory brain lesions, the great majority of which stained positive for markers of the microglia-macrophage lineage. Analysis in time-staged brain lesions revealed elevated levels of CX3CR1 mRNA in microglia in the periplaque zone, as well as a dramatically enhanced accumulation of CX3CR1 expressing cells within the early-active, late-active and inactive, demyelinated lesions.

**Conclusion:** Our data demonstrate constitutive and regulated expression of the chemokine CX3CL1 and its receptor CX3CR1 by neurons/astrocytes and microglia, respectively, within the normal and inflamed rat brain. Our findings propose a mechanism by which neurons and reactive astrocytes may control migration and function of the surrounding microglia. In addition, the accumulation of CX3CR1 expressing cells other than microglia within the inflammatory brain lesions indicate a possible role for CX3CL1 in controlling invasion of peripheral leucocytes to the brain.

**Background**

Chemokines are key mediators controlling infiltration of leukocytes to inflamed areas. They consist of a class of related proteins that exert chemotactic properties on leukocytes via interactions with select members of the G-protein coupled, cell membrane-spanning receptors (GPCRs). The so far 50 identified chemokines are divided into 4 subgroups, the XC, CC, CXC and CX3C chemokines, and the corresponding GPCRs are accordingly denominated XCR (presently one member), CCR (11 deorphanized members), CXCR (6 members) and CX3CR (one single member). Synthesis of chemokines is rapidly induced in damaged or infected tissues and the cell-specific expression of chemokine receptors combined with the situation-specific production of their chemokine ligands provide cues to attract appropriate cell populations to combat invading organisms and neoplastic cells and to clear and repair damaged tissues. Chemokines are also thought to drive chronic inflammatory processes and this has fuelled hopes that pharmacological intervention of the situation-specific production of their chemokine ligands may control the infiltration of pathogenic cells to sites of injury or infection.

CX3CL1 (alternative names: fractalkine or neurotactin) was identified in 1997 as a chemokine of 373 amino acids with, for the chemokine family, an atypical structure, a chemokine domain tethered on top of a mucin-like domain which is followed by a single transmembrane spanning domain and a short cytoplasmic tail [2-4]. CX3CL1 is expressed within the brain, heart, lung, kidney, muscle and testis [4-8] where it interacts with a single GPCR, CX3CR1 [9,10] to trigger chemotaxis and adhesion [10-13] of CX3CR1 expressing cells, including neutrophils, monocytes, NK cells and Th-1 polarized T cells [10,14]. Studies of expression profiles, functional role in *in vitro* and *in vivo* systems and genetic associations to diseases have provided promising clues to a potential role of CX3CL1 and its receptor in, among others, rheumatoid arthritis [15-17], allograft rejections [18] and atherosclerosis [19-21].

The physiological role of CX3CL1 and its receptor in the brain, however, is less clear. Expression of CX3CL1 within the brain is localized to neurons [22-25], whereas CX3CR1 is expressed by brain microglia [6,24-26]. Anatomical studies on the facial nerve trigger increased expression of CX3CL1 among the severed motor neurons in the facial nucleus [6] and a similar response was recently observed following intraperitoneal injection of prion proteins [22]. Induction of experimental autoimmune encephalomyelitis (EAE; an animal model for multiple sclerosis) in the mouse has also been associated with CX3CL1-like immunoreactivity in blood vessels within the inflammatory brain lesions [3]. This finding is complemented by the increased levels of CX3CR1 mRNA in the spinal cord of rats with EAE, as demonstrated by RNAse protection assay [27]. CX3CL1 has moreover been shown to regulate microglia functions, including CX3CL1-induced mobilization of intracellular Ca2+, chemotaxis and the inhibition of Fas-mediated apoptosis *in vitro* [6,23,28]. This is reflected in the activation of microglia following injection of CX3CL1 *in vivo* to the rat brain parenchyma [22], indicating a potential role for CX3CL1 and CX3CR1 in mediating neuronal-microglial cross talk under normal and pathological conditions. In addition, previous claims of CX3CL1 expression in endothelial cells [3,15,16,29-32], combined with CX3CR1 on monocytes and Th-1 cells [5,14-16,33,34] may indicate a role in attracting pathogenic cells to sites of neuroinflammation, as well.

Multiple sclerosis (MS) is a chronic inflammatory disease of the CNS. It is associated with local activation of microglia and astroglia, infiltration of activated macrophages
and T cells, active degradation of myelin and damage to axons and neurons. The disease often develops from isolated self-limiting episodes with various neurological manifestations, including paralysis, to persistent, accentuated loss of neurological functions. The neuroinflammatory component of the disease is, at least in initial phases, thought to mediate important aspects of the clinical manifestations. The proposed role for CX3CL1 in the control of microglia activation and leukocyte infiltration places this chemokine/receptor pair in a potentially strategic position to control key aspects in the pathological events that are associated with development of brain lesions in MS. In this study, we examine this hypothesis further by analyzing the distribution, kinetics, regulation and cellular origin of CX3CL1 and CX3CR1 mRNA expression in the CNS of rats with MOG-induced EAE. The expression of CX3CL1 and its receptor was studied with in situ hybridization histochemical detection of their mRNA with radio labeled cRNA probes in combination with immunohistochemical staining of phenotypic cell markers. Our findings suggest that CX3CL1 and its receptor may control aspects of the neuroinflammatory processes in MOG-induced EAE, and possibly also MS.

**Methods**

**Animals**

Inbred female DA.RT1av1 rats were obtained from B&K Sollentuna, Stockholm, Sweden. All rats were housed under specific pathogen-free conditions to keep the influence of additional environmental factors, beside immunization, as low as possible. Female DA rats 10–14 weeks of age (150–200 g) were used. All animal experiments were approved and performed in accordance with Swedish national guidelines.

**Preparation of MOG**

The N-terminal sequence of rat MOG (amino acids 1–125) was expressed in Escherichia coli and purified to homogeneity by chelate chromatography [35]. The purified proteins in 6 M urea were then dialyzed against PBS to obtain a preparation that was stored at -20°C.

**Induction and assessment of EAE**

Rats were anaesthetized with methoxyflurane and injected intradermally at the base of the tail with 0.2 ml inoculum, containing 20 µg recombinant rat MOG in saline, emulsified (1:1) with incomplete Freund’s adjuvant (IFA; Difco, Detroit, MI). Rats were clinically scored and weighted daily from day 7 post-immunization (p.i.) until day 30 p.i. by two alternating investigators. The clinical scoring was as follows: 0 = no illness, 1 = tail weakness or tail paralysis, 2 = hind leg paraparesis, 3 = hind leg paralysis, 4 = complete paralysis, moribund state, or death. A disease remission was defined as an improvement in disease score from either 3 or 4 to 1, or from 2, 3 or 4 to 0 that was maintained for at least 2 days consecutively. A relapse was defined as an increase in the clinical deficit of at least two points that lasted for at least 2 days.

**Histopathology**

Tissues where obtained from healthy, non-immunized rats or rats sampled on day 8, 13, 18, 21, 24, 29 and 40 p.i. Rats were deeply anaesthetized with methoxyflurane and subjected to perfusion via aorta with 4% paraformaldehyde. Organs were dissected out, routinely embedded in paraffin wax and sectioned at 5 µm. Histopathological evaluation was performed on transverse sections of the forebrain, midbrain, brainstem and 17 different rostro-caudal levels of the spinal cord, using hematoxylin and eosin (HE). Luxol fast blue/periodic acid Schiff’s (PAS) staining and Bielschowsky silver impregnation, to assess inflammation, demyelination, and axonal pathology, respectively [36,37].

**Preparation of radioactively labeled cRNA probes**

Preparation of radioactively labeled cRNA probes encoding rat CX3CL1 and CX3CR1 was carried out as previously described [38]. Briefly, antisense and sense cRNA probes were transcribed in vitro with T3 or T7 RNA polymerase in the presence of 35S-uridine triphosphate (35S-UTP; NEN – DuMedical, Sollentuna, Sweden). After removal of unincorporated nucleotides by Quick Spin columns (Boehringer Mannheim, Indianapolis, IN), the specific activities of all the probes were 1–3 × 10⁹ dpm/ug. The CX3CL1 and CX3CR1 cRNA probes were transcribed from cDNA fragments cloned into pDP18 CU minus plasmid vector (Ambion, Austin, Texas). These cDNA fragments correspond to a 450 base pair cDNA fragment of rat CX3CL1 (from 20–469 bp, GeneBank accession number AF030358) and a 882 base pair cDNA fragment of rat CX3CR1 (GenBank accession number RN04808), respectively, and were generated by RT-PCR using sequence-specific oligonucleotide primers. The identities of the cloned cDNA fragments were finally confirmed by sequencing and database comparisons. Restriction enzymes and RNA polymerases were obtained from Promega (Madison, WI).

**In situ hybridization and immunohistohistochemistry**

To detect expression of CX3CL1 and CX3CR1 mRNA, in situ hybridization experiments were performed on sections from rat CNS. Hybridization and autoradiography were carried out as previously described [39]. Briefly, tissue sections were mounted on Superfrost plus slides (Super Frost Plus, Pittsburgh, USA) and dried under vacuum overnight after deparaffination in xylene, pre-treated in a microwave oven for 10 minutes at 97°C in 10 mM SSC (pH 6.0) and dehydrated in ethanol. As controls, radio labeled sense probes were transcribed in the sense orientation and hybridized to slides as processed in parallel. After application of 100 ul of hybridization solution...
To identify the cellular phenotypes of the CX3CL1 or CX3CR1 expressing cells, an immunohistochemical staining protocol was directly applied following the in situ hybridization step, as previously described [39]. The following monoclonal primary antibodies were used: an antibody specific for rat monocytes and macrophages (ED-1, Serotec, diluted 1/500) or an antibody reactive with glial fibrillary acidic protein (GFAP; G-A-5 diluted 1/20; Boehringer – Mannheim). Analysis for expression of CX3CL1 or CX3CR1 in neurons was performed, using an antibody reactive to a neuronal specific protein (NeuN [40]) diluted 1/100, Chemicon). Notably, as the NeuN antigen proved to be sensitive to the present conditions, we selected to compare the distribution of NeuN protein and CX3CL1 or CX3CR1 mRNA independently on consecutive tissue sections. A biotinylated sheep anti-mouse IgG antibody (Life Sciences) served as the secondary reagent, with the avidin biotin peroxidase (ABC) detection system (ABC Elite, Vector Laboratories) combined with the ABC avidin biotin peroxidase (ABC) detection system (ABC Elite, Vector Laboratories). Finally, a biotinylated lectin (GSI-B4, Vector Laboratories) served as the secondary reagent, with the avidin biotin peroxidase (ABC) detection system (ABC Elite, Vector Laboratories). In total, 8 EA lesions, 8 LA lesions, 7 DM lesions, 8 PPWM areas and 9 NWM areas were included in the analysis. Data were statistically evaluated with ANOVA, followed by Tukey’s multiple comparison test. A P value < 0.05 was considered to be statistically significant.

Imaging
Bright-field images were captured with a Kappa DX-30 digital camera mounted on a Leica microscope. Digital images were imported into Adobe Photoshop (v. 6.0), where they were adjusted to balance and optimize brightness, contrast, and sharpness. Individual files were exported to Canvas (v. 8.0) for assembly into plates, which were rendered at initial resolution of 300 dpi.

Results
Expression of mRNA encoding CX3CL1 and its receptor in the normal rat brain and spinal cord
Radio labeled antisense cRNA probes transcribed from cDNA encoding rat CX3CL1 (Fig. 1) and its receptor, CX3CR1 (data not shown), were initially hybridized in situ to 5 µm tissue section obtained throughout the entire rat brain and spinal cord. In the forebrain, cells expressing high levels of CX3CL1 mRNA were detected throughout the olfactory bulb, cerebral cortex, amygdala, globus-pallidus and thalamus (Fig. 1). These cells manifested, with few exceptions, a neuronal phenotype and co-distributed with cells staining positive for the pan-neuronal marker NeuN (exemplified in Fig. 5a, b at the spinal cord level). High levels of CX3CL1 mRNA expression were also detected in all pyramidal cells within the hippocampal formation (Fig. 1). Significantly lower, but still clearly detectable, levels of CX3CL1 mRNA were observed within all aspects of the hypothalamus (Fig 1), with neurons within the ventromedial nucleus displaying the strongest labeling. In the mesencephalon, pons, medulla oblongata and the spinal cord low to medium expression levels were detectable, levels of CX3CL1 mRNA were observed within all aspects of the hypothalamus (Fig 1), with neurons within the ventromedial nucleus displaying the strongest labeling. In the mesencephalon, pons, medulla oblongata and the spinal cord low to medium expression levels were...
uniformly detected in neuronal-like cells. A notable exception was the cerebellum, where very low levels of expression were detected within granule and pyramidal cells whereas neuronal-like cells in the deep cerebellar nuclei expressed CX3CL1 mRNA at medium levels (Fig. 1).

Tissue sections hybridized in parallel with a radio labeled cRNA probe transcribed in the sense orientation did not reveal any hybridization signal above background levels (data not shown).

Figure 1
Distribution of CX3CL1 mRNA expressing cells in the normal rat brain. Coronal sections sampled at regular intervals throughout the rostro-caudal extent of the normal rat brain hybridized with a 35S-labeled antisense-cRNA probe encoding rat CX3CL1. Cells expressing mRNA encoding the chemokine are visualized as accumulations of white silver grain in this microscopic darkfield illumination at low magnification. The letters in each subfigure refer to the approximate levels according to the Paxinos stereotaxic brain atlas [61]. The highest levels of CX3CL1 mRNA were detected exclusively within the grey matter of the cerebral cortex (A:a, B:a, C:a, D:a), hippocampus (C:b), septum (B:c), thalamus (C:d) and striatum (B:e). Medium to low level expression was detected in the hypothalamus (C:f), pons (E:g), mesencephalon (D:h), medulla oblongata (not shown) and spinal cord (F:i). The cerebellum (E:j) was devoid of CX3CL1 expression, except for a low level of expression in the deep cerebellar nuclei. Parallel sections hybridized with a sense-transcribed CX3CL1 cRNA probe of equal specific activity did not reveal signals above background levels.
In addition to the expression of CX3CL1 mRNA among neuronal-like cells within the rat brain and spinal cord, we also detected low-to medium expression of CX3CL1 in a few, solitary cells dispersed throughout the white matter areas. These cells manifested a flattened, elongated morphology (data not shown) and were not positively stained in dual labeling experiments for CX3CL1 mRNA with phenotypic markers for macrophages/microglia or astrocytes. No expression of CX3CL1 mRNA was detected in cells associated with the cerebral vasculature and the meninges, including the endothelial cells themselves.

In consecutive tissue sections, in situ hybridization with a radio labeled antisense cRNA probe encoding rat CX3CR1 revealed a low-to-medium expression within cells uniformly distributed throughout the entire neuraxis (data not shown). The morphology of these cells, as well as their positive labeling with C5I-B4 (Griffonia simplicifolia isoelectin B4; stains microglia, macrophages and endothelial cells) identified them as being inactive microglia (data not shown). No detectable expression was observed over other cells, including neurons and perivascular and meningeal macrophages. Hybridization with a sense cRNA probe transcribed from the same cDNA did not reveal a signal above background levels (data not shown).

Expression of mRNA encoding CX3CL1 and its receptor in the CNS of rats with MOG-EAE

To explore the role of CX3CL1 and its receptor in the control of inflammatory cascades in MS, we examined their expression and regulation in the CNS of rats with MOG-induced EAE. In inbred DA rats, this disease manifested a mostly relapsing-remitting disease course with an initial paralytic episode, commencing around day 9–13 followed by a partial or complete remission and then a relapse of paresis (Fig. 2). In some rats the initial (acute) paresis progressed directly into a prolonged paralysis without any intervening remission of symptoms. In a minority of the rats the acute episode spontaneously resolved without further clinical signs of disease. The acute phase of paresis was characterized histopathologically by astroglial and microglial activation and perivascular and submeningeal infiltration of lymphocytes, macrophages and granulocytes. The inflammatory lesions were mostly confined to the spinal cord and, in some rats, the optic nerve and the cerebellar white matter. In rats that exhibited a clinical relapse the inflammation followed generally the pattern observed during the acute phase with submeningeal and perivascular lesions. However, the inflammatory reaction was often more extensive with numerous confluent lesions that covered substantial areas of the spinal white matter (Fig. 4), sometimes extending into the grey matter areas. Inflammatory lesions were at this stage closely associated with a marked demyelination as well as axonal degeneration and loss of axonal density.

There was a distinct transition in cellular composition observed within the inflammatory lesions, from predominantly lymphocytes and granulocytes in the acute phase lesions to an overwhelming presence of macrophages and microglia with only a few granulocytes throughout the inflammatory lesions during the clinical relapse. These phagocytic cells exhibited obvious signs of uptake and degradation of myelin components. This pattern of paresis and histopathological alterations was generally in accordance with previous studies [37,42], to which interested readers are referred for further details on the disease pathology.

For the following studies we selected rats that conformed to the typical relapsing-remitting disease phenotype (Fig. 2). In situ hybridization experiments revealed an uncompromised neuronal expression of CX3CL1 mRNA throughout the entire CNS at all time points examined, except for a tendency to a reduced level of expression in grey matter regions which were notably infiltrated with inflammatory cells (data not shown). In addition, increased expression of CX3CL1 mRNA was evident in a small number of non-neuronal cells within the inflammatory lesions. Double-labeling experiments showed those cells to stain positive for the astroglial marker glial fibrillary acidic protein, GFAP (Fig. 5). No hybridization signal above background levels was detected in cells staining
positive for GSI-B4 (e.g. macrophages/microglia and endothelial cells). Tissue sections hybridized in parallel with a sense-transcribed CX3CL1 cRNA probes did not generate hybridization signals above background levels (data not shown).

In situ hybridization with an antisense cRNA probe for CX3CR1 demonstrated a low, constitutive expression of the receptor in cells evenly distributed throughout the spinal cord of healthy, non-immunized control rats (n = 3) and presymptomatic rats (day 8 p.i, n = 3) (Fig. 3). The morphology and positive staining for GSI-B4 identified these cells as being inactive microglial cells. Rats examined at various stages following onset of clinically manifest MOG-induced EAE (day 13 p.i, acute phase, n = 3; day 18 p.i, remission phase, n = 3; day 21 p.i, early relapse phase, n = 3; day 24 p.i, mid relapse phase, n = 3; day 29 p.i, late relapse phase, n = 3) demonstrated a clear visual increase in CX3CR1 mRNA per cell, as well as a notably increased density of CX3CR1 mRNA expressing cells, within the inflammatory areas (Fig. 3 and 4). These aggregates of CX3CR1 mRNA expressing cells were closely overlapping with the inflammatory lesions, being prominent in the perivascular and submeningeal lesions during the acute phase and with a few remaining lesions detectable during the remission phase. In rats examined at various time points of the relapse phase the aggregation of cells expressing high levels of CX3CR1 mRNA closely followed the areas of expanding lesions. The great majority of the CX3CR1 mRNA expressing cells were at all stages of disease positively stained with GSI-B4 isoelectin as well as with the marker for active phagocytosis, ED-1. While all GSI-B4 positive, CX3CR1 mRNA expressing cells in PPWM regions displayed abundant ramified processes identifying them as resident microglia, the morphology of the GSI-B4 positive, CX3CR1 mRNA expressing cells within EA, LA and DM lesions was consistent with both macrophages and microglia in an activated, phagocytic state (Fig. 5). Occasional GSI-B4 negative, CX3CR1 mRNA expressing cells were identified within the inflammatory lesions. These cells had rounded or slightly elongated nuclei and were of lymphocyte-like size. However, the great majority of lymphocytes within the lesions did not express CX3CR1 mRNA (data not shown).
Quantification of CX3CR1 mRNA-expressing cells in relation to the stage of demyelinating activity

To further characterize the distribution of CX3CR1 mRNA-expressing cells in MOG-induced EAE, we performed a quantitative analysis in defined time-staged lesions. The strongest expression of CX3CR1 mRNA was found in LA areas, which contained a significantly higher density of silver grains per square unit compared to EA areas \( (p < 0.05) \), DM areas \( (p < 0.05) \), PPWM regions \( (p < 0.001) \) and NWM \( (p < 0.001) \) (Table 1, Figure 6a). In EA and DM areas, the expression of CX3CR1 mRNA was significantly higher compared to PPWM \( (p < 0.001) \) and NWM \( (p < 0.001) \). Although PPWM regions tended to show a higher density of silver grains per square unit compared to NWM, this difference was not statistically significant (Table 1, Figure 6a). The actual number of CX3CR1 mRNA-expressing cells was three-fold higher in lesional areas compared to PPWM and NWM but did not differ significantly between EA, LA and DM. The overwhelming majority of the CX3CR1 mRNA-expressing cells stained positive for GSI-B4 isolectin, identifying them as macrophages/microglia (Table 1, Figure 6b). Although not all GSI-B4+
Figure 5
Phenotyping of CX₃CL₁ and CX₃CR₁ expressing cells. CX₃CL₁ mRNA expressing cells (upper left). Immunohistochemical staining for the neuronal marker NeuN (upper right) performed on a parallel tissue section. Dual staining for CX₃CL₁ mRNA and the astrocyte marker GFAP (lower left). Combined staining for CX₃CR₁ mRNA and the microglial marker GS1-B4 isolectin (lower right).
cells expressed CX3CR1 mRNA, there was a significant ($p < 0.0001$) correlation between the total number of GSI-B4+ cells and the density of silver grains per square unit (Table 1, Figure 6c).

**Discussion**

This study was designed to provide further insights into the mechanisms of proinflammatory cell trafficking into the CNS in MS. Our results show that the chemokine CX3CL1 is expressed, and actively regulated, within inflammatory CNS lesions in rats with MOG-induced EAE, a rodent model of MS. In addition, we demonstrate that cells expressing the CX3CR1 receptor, the majority of which are potentially pathogenic phagocytic cells (i.e. macrophages and/or microglia), are densely accumulating within the inflammatory lesions. This is consistent with the hypothesis for a role of CX3CL1-CX3CR1 in the local control of leukocyte infiltration into CNS lesions in MOG-EAE rats, and possibly also MS. The constitutive CX3CL1 and CX3CR1 expression by neurons and microglia, respectively, even in the healthy rat brain, indicates a potential mechanism whereby neurons control microglia functions in the intact brain tissue, as well.

Our present findings of constitutive expression of CX3CL1 within the normal rat brain are in agreement with previous reports where CX3CL1 mRNA [24,25,43] and protein [25,43] was demonstrated in most CNS neurons of healthy rats. Similar results have also been obtained in the mouse [4], rhesus monkey [25] and human [44] brain. It is interesting to note that the levels of CX3CL1 mRNA differed greatly between different CNS regions, possibly indicating a more pronounced role for neuronal CX3CL1 in many forebrain structures, i.e. cerebral cortex, hippocampus and striatum. Our demonstration that CX3CL1 mRNA expression is induced in astrocytes within EAE lesions is novel although the data are in accordance with study of humans with HIV-associated dementia where CX3CL1 immunoreactivity was detected in astrocytes [45]. Induced expression of CX3CL1 in astrocytes was also observed following intraparenchymal administration of prion protein to the rat brain [22]. Co-cultivation of human astrocytes and HIV-infected macrophages also resulted in increased CX3CL1 immunoreactivity in astrocytes [45] and stimulation of rat [23] and human [46] astrocytes with TNF-$\alpha$ and IL-1$\beta$ or INF-$\gamma$ in vitro has been shown to up regulate CX3CL1 mRNA levels. A recent immunohistochemical study of MS- and normal brain tissue demonstrates a constituent CX3CL1 expression in astrocytes and an increased expression in human adult astrocyte cultures stimulated with pro-inflammatory cytokines, but fail to demonstrate an upregulation of CX3CL1 in MS patients [47]. However, these data collectively indicate that astrocytes are capable of upregulating CX3CL1 expression in inflamed or injured brain tissues.
In contrast to the observed expression of CX3CL1 in neurons and astrocytes, we were not able to confirm previous findings in EAE-afflicted mice [2] where endothelial immunoreactivity for CX3CL1 was demonstrated within inflamed brain lesions. Our findings are corroborated by a recent study by Schwaeble et al. [25] in which no CX3CL1 mRNA expression was detected within the endothelium of EAE rats and mice. Possible explanations for the contradictory results are differences in the sensitivity of the detection methods used or a potential non-specific, immunohistochemical cross-reactivity to other proteins within the endothelium in the study by Bazan et al. [2]. An alternative explanation would be if the secreted form of CX3CL1, which is produced within the inflamed brain parenchyma by neurons and astrocytes, is transcytosed in an abluminal-to-luminal direction for presentation to blood leukocytes in a similar manner to what previously have been described for IL-8 and RANTES [48]. It is, however, important to note that endothelial cells outside the CNS have convincingly been demonstrated to express CX3CL1 mRNA and protein [6, 8, 29-32]. CX3CL1 expression by the brain endothelium, which may be below the detection limit of our assay, therefore remains a tantalizing possibility by which blood leukocytes may become attracted to migrate across the blood-brain barrier into inflammatory CNS lesions of MOG EAE rats.

Our present studies of CX3CR1 expression in the rat brain confirm previous findings by Harrison et al [43], Nishiyori et al [24] and others by demonstrating that microglia express CX3CR1 mRNA constitutively within the normal rat brain. These findings are also consistent with previous demonstrations that CX3CL1 increases microglial migration [43], proliferation [49], survival [28], intracellular recruitment of calcium [43] and secretion of cytokines and metalloproteases [50]. In addition, we demonstrate that CX3CR1 mRNA expressing cells are rapidly accumulating at high densities within the inflammatory CNS lesions of rats with MOG-induced EAE, confirming previous observations [41]. Interestingly, those cells amassed throughout most kinetic stages of the lesions, with the most conspicuous densities detected in the late active stages. It is tempting to speculate about a down-regulatory role of CX3CR1 expression in these late lesional stages, based on the possible induction of nonsignaling CX3CR1 receptors [51]. The overwhelming majority of the CX3CR1 mRNA expressing cells within the lesional areas were phagocytic cells (i.e. macrophages and/or microglia) as demonstrated in double-labeling protocols with the GSI-B4 isoelectric or the ED-1 antibody. However, a few additional, non-GSI B4 labeled, CX3CR1 mRNA expressing cells were also detected within the CNS lesions. These cells may be speculated to correspond to infiltrating blood leukocytes, such as NK cells, γδ T cells and/or terminally differentiated CD4+ and CD8+ T cells, which previously have been described to express CX3CL1 receptors and/or to respond functionally upon CX3CL1 stimulation [14, 15, 33, 52, 53]. However, the majority of the lymphocyte-like cells within the inflammatory lesions of the present rats did not express CX3CR1 mRNA. Notably, no expression of CX3CR1 mRNA was detected in GFAP-labeled astrocytes (data not shown) or neuronal-like cells. This contrasts to earlier findings of CX3CR1-like immunoreactivity within neurons of a rat model for prion disease [22], in humans with HIV encephalitis [44] and in vitro cultivated hippocampal neurons [54]. Hulshof et al. [47] found weak to moderate neuronal CX3CR1-like immunoreactivity in the cortical grey matter, depending on the tissue sample observed. Those data suggest that some populations of neurons may indeed have the capacity to express CX3CR1 under certain conditions.

Our present data are thus consistent with a role for CX3CL1 in the rat CNS, both during healthy and inflammatory conditions. The constitutive expression of CX3CL1 and its receptor on neurons and microglia respectively demonstrates that this chemokine-receptor pair is not normally promoting inflammation. Their function may under these conditions possibly be inert but CX3CL1, which is normally linked physically to the neuronal membrane via a spacer domain and a transmembrane spanning motif [2], may alternatively mediate a direct contact between neurons and neighboring microglia via

### Table 1: Quantification of CX3CR1 mRNA expressing cells per square unit in rat EAE lesions (mean ± SEM)

|                      | NWM | PPWM | EA  | LA  | DM  |
|----------------------|-----|------|-----|-----|-----|
| Density of silver   | 39.4±8.2 | 70.8±7.2 | 220.3±17.4a | 276.3±14.8b | 208.4±18.3a |
| grains* per 1.9 x 10^4 µm^2 |     |      |     |     |     |
| Total number of GSI-B4+ cells per 1.9 x 10^4 µm^2 | 11.0±1.5 | 18.6±1.6 | 65.3±5.3a | 68.1±3.3a | 59.8±2.4a |
| Number of GSI-B4+/CX3CR1+ cells per 1.9 x 10^4 µm^2 | 5±0.9 | 12.4±1.3 | 46.1±7.4a | 50.7±3.3a | 46.0±3.8a |
| Number of GSI-B4+/CX3CR1+ cells per 1.9 x 10^4 µm^2 | 0±0 | 0±0 | 0±0 | 2.1±0.7a | 0.8±0.4 |

*Silver grains: defined as areas exceeding the mean background level + 11 SD
† Statistically significant against NWM and PPWM
§ Statistically significant against NWM, PPWM, EA and DM
its proadhesive properties [2]. Microglia are highly reactive to insults to brain tissue and may inflict permanent damage if not kept in check. A CX3CL1-mediated interaction between neurons and surrounding microglia may under healthy conditions provide a mechanism by which neurons subdue the proinflammatory and neurotoxic capacity of microglia. This notion is supported by recent findings from in vitro studies where CX3CL1 inhibited neuronal death following the stimulation in vitro of cocultured microglia and hippocampal neurons with lipopolysaccharide, LPS [55]. In this study, CX3CL1 was also demonstrated to inhibit LPS stimulated activation of microglia and associated TNF-α synthesis [55]. Moreover, endogenous CX3CL1 has also been shown to inhibit the increased levels of TNF-α and 8-isoprostane in the hippocampus and cerebrospinal fluid following intracerebroventricular injections of LPS [56]. In another study, CX3CL1 protected neurons in vitro from the neurotoxic properties of platelet activating factor or the HIV envelope protein, Tat [44]. In contrast, under conditions where neurons and their axonal and dendritic projections are injured, as is frequently the case in EAE and MS, CX3CL1 is likely to be cleaved and released from the neuronal membrane by locally acting metalloproteases [57]. This would create a chemotactic gradient that, in combination with other locally active proinflammatory mediators, may subserve the extensive accumulation and activation of microglia within injured brain sites as observed in the present study. In addition, the soluble form of CX3CL1 may also contribute to the infiltration of CX3CR1-expressing leukocytes, including macrophages and effector T and NK cells. These cell types have crucial roles in EAE as mediators of tissue destruction and/or disease regulation [58]. A functional significance of the soluble CX3CL1 / CX3CR1-pathway is suggested by the present demonstration of CX3CR1 expression in macrophage-like cells and a small fraction of lymphocyte like cells. Interestingly, concurrent studies have provided functional evidences that CX3CR1 and its ligand serve as important mediators of inflammation and pathology in animal models models for atherosclerosis, transplant rejections, glomerulonephritis and stroke [12,19,29,59]. Studies in mice with targeted deletions of the CX3CL1 or CX3CR1 genes have, however, failed to provide information regarding a contributory function for this chemokine-receptor pair in EAE. CX3CL1 +/− mice [60] or CX3CR1 +/− mice [18] developed EAE in a manner not significantly deviating from wildtype mice. Furthermore, CX3CR1 +/− mice did not manifest alterations in the microglia responses around injured/dying motor neurons in a peripheral axotomy model [53]. These studies suggest a redundant compensatory mechanism by other chemotactic factors or a more subtle role of this chemokine-receptor pair in these mouse models for MS. The aforementioned studies, which proposed a neuroprotective role for CX3CL1, would also warrant a more thorough investigation of the long-term outcome as regards paralysis and neuronal injuries in EAE-challenged CX3CL1, or CX3CR1, deficient mice. A definite assignment of the role of CX3CL1 and its receptor in normal and inflamed or injured CNS conditions will await conceptual testing in animal disease models using more informative tools such as selective immunoneutralizing antisera, peptide antagonists or non-peptidergic CX3CR1 antagonists delivered at various stages of the disease.

Conclusion

- We have provided data to demonstrate constitutive and regulated expression of the chemokine CX3CL1 and its receptor CX3CR1 by neurons/astrocytes and microglia, respectively, within the normal and inflamed rat brain.

- Our findings propose a mechanism by which neurons and reactive astrocytes may control migration and function of the surrounding microglia.

- In addition, the accumulation of CX3CR1 expressing cells other than microglia within the inflammatory brain lesions indicate a possible role for CX3CL1 in controlling invasion of peripheral leucocytes to the brain.

Competing interests

The author(s) declare that they have no competing interests.

Authors’ contributions

Design of studies (DS, SE, EW, TO, HL, AE-D), cloning of plasmid construct (AE-D), experimental induction of EAE and preparation of tissues (SE, DS, MN), in situ hybridization and immunohistochemical histochemical stainings (DS, MN), analysis of data (DS, SE, HL, A-LB, AED), writing/reviewing of manuscript (all authors). All authors have read and approved the final manuscript.

Acknowledgements

The study was supported by The Swedish Medical Research Council, The Swedish Strategic Funds, The Swedish Society for Neurologically Disabled and Montel Williams foundations.

References

1. Karpus WJ: Chemokines and central nervous system disorders. J Neurol 2001, 248:493-500.
2. Bazan JF, Bacon KB, Hardiman G, Wang W, Soo K, Rossi D, Greaves DR, Zlotnik A, Schall TJ: A new class of membrane-bound chemokine with a CXC3C motif. Nature 1997, 385:640-644.
3. Pan Y, Lloyd C, Zhou H, Dolich S, Deeds J, Gonzalez JA, Vath J, Gasselin M, Ma J, Dussault B, Woolf E, Alperin G, Culpepper J, Gutierrez-Ramos JC, Gearing D: Neurotactin, a membrane-anchored chemokine upregulated in brain inflammation. Nature 1997, 387:611-617.
4. Rossi DL, Hardiman G, Copeland NG, Gilbert DJ, Jenkins N, Zlotnik A, Bazan JF: Cloning and characterization of a new type of mouse chemokine. Genomics 1998, 47:163-170.
5. Foussat A, Coulomb-L’Hermine A, Gosling J, Krzyzek R, Durand-Gasselin I, Schall T, Balian A, Richard Y, Galanaud P, Emilie D: Frac-
talline receptor expression by T lymphocyte subpopulations and in vivo production of fractalkine in human. Eur J Immunol 2000, 30:875-887.
6. Harrison JK, Jiang Y, Wees EA, Salafarzadeh MN, Liang HK, Feng L, Belardini L: Inflammatory agents regulate in vivo expression of fractalkine in endothelial cells of the rat heart. J Leukoc Biol 1999, 66:373-344.
7. Lucania AD, Chadwick N, Warren B, Jewell DP, Gordon S, Powrie F, Greaves DR: The transmembrane form of the CX3CL1 chemokine fractalkine is expressed predominantly by epithelial cells in vivo. Am J Pathol 2001, 158:855-866.
8. Muehlhofer A, Saubermann LJ, Gu X, Luedtke-Heckenkamp K, Xavier R, Blumberg RS, Podolsky DK, MacDermott RP, Reinecker HC: Fractalkine is an epithelial and endothelial cell-derived chemooattractant for intraepithelial lymphocytes in the small intestinal mucosa. J Immunol 2000, 164:3368-3376.
9. Combaud C, Salzededo K, Smith ED, Tiffany HL, Berger EA, Murphy PM, de Prost D, Combadiere C: Identification of CX3C chemokine fractalkine and a fusion coreceptor for HIV-1. J Biol Chem 1998, 273:23799-23804.
10. Imai T, Hieshima K, Haskell CA, Baba M, Nagira M, Nishimura M, Kakuizaki M, Takagi S, Nomiya H, Schall TJ, Yoshie O: Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion. Cell 1999, 91:521-530.
11. Feng AM, Robinson LA, Steeber DA, Tedder TF, Yoshie O, Imai T, Patel DD: Fractalkine and CX3CR1 mediate a novel mechanism of leukocyte capture, firm adhesion, and activation under physiologic flow. J Exp Med 1998, 188:1431-1419.
12. Haskell CA, Celly MD, Charo IF: Molecular uncoupling of fractalkine-mediated cell adhesion and signal transduction. Rapid flow arrest of CX3CR1-expressing cells is independent of cell-protein activation. J Biol Chem 1999, 274:10303-10308.
13. Haskell CA, Celly MD, Charo IF: Unique role of the chemokine domain of fractalkine in cell capture. Kinetics of receptor dissociation correlate with cell adhesion. J Biol Chem 2000, 275:34175-34182.
14. Stover CM, Schwabe WJ, Debre P, Aumont MC, Murphy PM, de Prost D, Combadiere C: Multiple sclerosis and in vivo production of fractalkine in human. J Neurol 2000, 247:6067-6072.
15. Nishiyori A, Minami M, Ohtani Y, Takami S, Yamamoto J, Kawaguchi T, Takagi S, Nomiyama H, Schall TJ, Yoshie O, Miyasaka N: Migration of CX3CR1-positive T cells producing type 1 cytokines and cytotoxic molecules into the synovium of patients with rheumatoid arthritis. J Clin Invest 2000, 106:133-140.
16. Rath JR, Volin MV, Haines GK 3rd, Dairaghi DJ, Trinder PK, Liningrier CM, Pennell NA, Streit WJ, Harrison JK: Chemokine receptor expression in cultured glia and rat experimental allergic encephalomyelitis. J Neuroimmunol 1998, 86:1-12.
17. Boehme SA, Lio FM, Maciejewski-Lenoir D, Conlon PJ: The chemokine fractalkine enhances Fas-mediated cell death of brain microglia. J Immunol 2000, 165:397-403.
18. Feng L, Chen S, Garcia GE, Xia Y, Siani MA, Botti P, Wilson CB, Harrison JK, Bacon KB: Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1 rapid conversion of crescentic glomerulonephritis to a diffuse proliferative glomerulonephritis. Kidney Int 1999, 56:612-620.
19. Geisler C, Morigi M, Ganser A, Pfeiffer D, Gabriel S, Schaller M, Boettcher S, Engel P, Brockhaus M, Tschopp J: Inflammatory agents regulate in vivo expression of CX3CL1/fractalkine in cultured human endothelial cells. Takahashi J Exp Med 2000, 192:127-139.
20. Villanueva M, Ramos S, Teyton L, Saz J, Marzo I, Jurado MI, Vazquez-Molinero T, Aragon A, Garcia M, Pio A, Conesa MA, Vela-Mas T: Multiple sclerosis and fractalkine receptor expression in human autologous peripheral blood neutrophils. Brain Pathol 2000, 10:153-160.
21. Burt AD, Saura M, Fernández M, Aragon A, García J: Multiple sclerosis and fractalkine receptor expression in human autologous peripheral blood neutrophils. Brain Pathol 2000, 10:153-160.
22. Murrey JR, Buck CR, Smith DM: NeuN, a neuronal specific nuclear protein in vertebrates. Development 1992, 116:201-211.
23. Maciejewski-Lenoir D, Chen S, Feng L, Maki R, Bacon KB: Characterization of fractalkine in rat brain cells: migratory and activation signals for CX3CR1-I expressing microglia. J Immunol 1999, 163:1628-1635.
24. Nishimura M, Umehara H, Nakayama T, Yoneda O, Hieshima K, Kakuizaki M, Takagi S, Ohtaki U, Hidemi Y, Satoh M, Kakuizaki K: Identification of CX3CR1. A chemotactic receptor for the human CX3C chemokine fractalkine and a fusion coreceptor for HIV-1. J Biol Chem 1998, 273:23799-23804.
25. Schwabe WJ, Stover CM, Schall TJ, Dairaghi DJ, Trinder PK, Liningrier CM, Pennell NA, Streit WJ, Harrison JK: Chemokine receptor expression in cultured glia and rat experimental allergic encephalomyelitis. J Neuroimmunol 1998, 86:1-12.
26. Boehme SA, Lio FM, Maciejewski-Lenoir D, Conlon PJ: The chemokine fractalkine enhances Fas-mediated cell death of brain microglia. J Immunol 2000, 165:397-403.
27. Feng L, Chen S, Garcia GE, Xia Y, Siani MA, Botti P, Wilson CB, Harrison JK, Bacon KB: Prevention of crescentic glomerulonephritis by immunoneutralization of the fractalkine receptor CX3CR1 rapid conversion of crescentic glomerulonephritis to a diffuse proliferative glomerulonephritis. Kidney Int 1999, 56:612-620.
28. Caroli J, Scheweckert VL, Eddy RL Jr, Shows TB, Gray PW: The origin of G-protein-coupled receptors encoding V28 is closely related to genes for chemokine receptors and is expressed in lymphoid and neural tissues. Gene 1995, 163:295-299.
29. Amor S, Gromeo N, Lintong C, Morris MM, Dornmair K, Gardinier MV, Matthieu LM, Baker D: Identification of epitopes of myelin oligodendrocyte glycoprotein for the induction of experimental allergic encephalomyelitis in SJL and Biozzi AB/H mice. J Immunol 1994, 153:4349-4356.
30. Kornak B, Scheck M, Weisert R, Wallstrom E, Steffler A, Olsson T, Lintong C, Schmidbauer M, Lassam N: Multiple sclerosis and chronic autoimmune encephalomyelitis: a comparative quantitative study of axonal injury in active, inactive, and remyelinated lesions. Am J Pathol 2000, 157:267-276.
31. Storch MK, Steffler A, Brehm U, Weisert R, Wallstrom E, Kerschenstein M, Olsson T, Lintong C, Lassam N: Myelin oligodendrocyte glycoprotein in the spectrum of multiple sclerosis pathology. Brain Pathol 1998, 8:681-694.
32. Combaud C, Arriola JL, Swanson LW: A complete protocol for in situ hybridization of messenger RNAs in brain and other tissues with radiolabeled single-stranded RNA probes. J Histochem 1995, 12:169-181.
33. Itayev S, Sunnenmark D, Berg AL, Nordvall G, Malmberg A, Lassam N, Wallstrom E, Olsson T, Eriksson-Dahlstrand A: Expression of CC chemokine receptor-1 selective antagonism reduces multiple sclerosis-like rat disease. J Neuroimmunol 2003, 142:75-85.
34. Mullen RJ, Buck CR, Smith AM: NeuroN, a neuronal specific nuclear protein in vertebrates. Development 1992, 116:201-211.
41. Sunnemark D, Eltayeb S, Wallstrom E, Appelsved L, Malmberg A, Lassmann H, Ericsson-Dahlstrand A, Piel F, Olsson T: Differential expression of the chemokine receptors CX3CR1 and CXCR1 by microglia and macrophages in myelin-oligodendrocyte-glycoprotein-induced experimental autoimmune encephalomyelitis. *Brain Pathol* 2003, 13:617-629.

42. Weisert R, Wallstrom E, Storch MK, Stefferl A, Lorentzen J, Lassmann H, Linnington C, Olsson T: MH C haplotype-dependent regulation of MOG-induced EAE in rats. *J Clin Invest* 1998, 102:1265-1273.

43. Harrison JK, Jiang Y, Chen S, Xia Y, Maciejewski D, McNamara RK, Streit WJ, Salafaracna MN, Adilkar S, Thompson DA, Botti P, Bacon KB, Feng LL: Role for neuronally derived fractalkine in mediating interactions between neurons and CX3CR1-expressing microglia. *Proc Natl Acad Sci U S A* 1998, 95:10896-10901.

44. Tong N, Perry SW, Zhang Q, James HJ, Guo H, Brooks A, Bal H, Kinnear SA, Fine S, Epstein LG, Dairaghi S, Schall TJ, Gendelman HE, Dewhurst S, Sharer LR, Gelbard HA: Neuronal fractalkine expression in HIV-1 encephalitis: roles for macrophage recruitment and neuroprotection in the central nervous system. *J Immunol* 2000, 164:1333-1339.

45. Pereira CF, Middel J, Jansen G, Verhoef J, Nottet HS: Enhanced expression of fractalkine in HIV-1-associated dementia. *J Neuroimmunol* 2001, 115:168-175.

46. Yoshida H, Imaiuzumi T, Fujimoto K, Matsuou N, Kimura K, Cui X, Matsumiya T, Tanji K, Shibata T, Tamo W, Kumagai M, Satoh K: Synergistic stimulation, by tumor necrosis factor-alpha and interferon-gamma, of fractalkine expression in human astrocytes. *Neurosci Lett* 2001, 303:132-136.

47. Hulshof S, van Haastert ES, Kuipers HF, van den Elsen PJ, de Groot CJ, van der Valk P, Ravid R, Biber K: CX3CL1 and CX3CR1 expression in human brain tissue: noninflammatory control versus multiple sclerosis. *J Neuropath Exp Neural* 2003, 62:899-907.

48. Middleton J, Neil S, Wintle J, Clark-Lewis I, Moore H, Lam C, Auer M, Hub E, Rot A: Transcytosis and surface presentation of IL-8 by venular endothelial cells. *Cell* 1997, 91:385-395.

49. Hatori K, Nagai A, Heisel R, Ryu JK, Kim SU: Fractalkine and fractalkine receptors in human neurons and glial cells. *J Neurosci Res* 2002, 69:418-426.

50. Cross AK, Woodroofe MN: Chemokine modulation of matrix metalloproteinase and TIMP production in adult rat brain microglia and a human microglial cell line in vitro. *Glia* 1999, 28:183-189.

51. Chen S, Luo D, Streit WJ, Harrison JK: TGF-beta1 upregulates CX3CR1 expression and inhibits fractalkine-stimulated signaling in rat microglia. *J Neuroimmunol* 2002, 133:46-55.

52. Al-Aoukaty A, Rolstad B, Giaid A, Maghazachi AA: MIP-3alpha, MIP-3beta and fractalkine induce the locomotion and the mobilization of intracellular calcium, and activate the heterotrimeric G proteins in human natural killer cells. *Immunology* 1998, 95:618-624.

53. Jung S, Aliberti J, Graemmel P, Sunshine MJ, Kreutzberg GW, Sher A, Littman DR: Analysis of fractalkine receptor CX(3)CR1 function by targeted deletion and green fluorescent protein reporter gene insertion. *Mol Cell Biol* 2000, 20:106-114.

54. Macucci O, Fatatis A, Simen AA, Miller RJ: Expression of CX3CR1 chemokine receptors on neurons and their role in neuronal survival. *Proc Natl Acad Sci U S A* 2000, 97:8075-8080.

55. Zujovic V, Benavides J, Vige X, Carter C, Taupin V: Fractalkine modulates TNF-alpha secretion and neurotoxicity induced by microglial activation. *Glia* 2000, 29:305-313.

56. Zujovic V, Schussler N, Jourdain D, Duverger D, Taupin V: In vivo neutralization of endogenous brain fractalkine increases hippocampal TNFalpha and 8-isoprostane production induced by intracerebroventricular injection of LPS. *J Neuroimmunol* 2001, 115:133-143.

57. Chapman GA, Moors K, Harrison D, Campbell CA, Stewart BR, Strijbos PJ: Fractalkine cleavage from neuronal membranes represents an acute event in the inflammatory response to excitotoxic brain damage. *J Neurosci* 2000, 20:RC87.

58. Hemmer B, Cepok S, Nessler S, Sommer N: Pathogenesis of multiple sclerosis: an update on immunology. *Curr Opin Neurol* 2002, 15:227-231.

59. Soriano SG, Amaravadi LS, Wang YF, Zhou H, Yu GX, Tonra JR, Fairchild-Huntress V, Fang Q, Dunmore JH, Huszar D, Pan Y: Mice deficient in fractalkine are less susceptible to cerebral ischemia-reperfusion injury. *J Neuroimmunol* 2002, 125:59-65.

60. Cook DN, Chen SC, Sullivan LM, Manfra DJ, Wiekowski MT, Prosser DM, Vassileva G, Lira SA: Generation and analysis of mice lacking the chemokine fractalkine. *Mol Cell Biol* 2001, 21:3159-3165.

61. Paxinos G, Watson C: *The Rat Brain in Stereotaxic Coordinates*, 4th edition. Academic Press; 1998.